Multi Cohort Study of Tazemetostat in Combination With Various Treatments For R/R Hematologic Malignancies

Relapsed/Refractory Clinical Trial

Official title:
ARIA: A Phase 1b/2, Open-label, Multi Cohort Trial of Tazemetostat in Combination With Various Treatments in Subjects With Relapsed or Refractory Hematologic Malignancies

Status Recruiting

Clinical Trial Summary

This phase 1b/2 trial studies how safely the EZH2 inhibitor tazemetostat works with other therapies in various hematological malignancies. Tazemetostat has been found to be a safe and effective drug that works in patients with relapsed refractory follicular lymphoma. Giving tazemetostat in combination with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05205252
Study type	Interventional
Source	Epizyme, Inc.
Contact	Clinical Trial
Phone	1 (855) 500-1011
Email	clinicaltrials@epizyme.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	December 22, 2021
Completion date	May 2028

View Details

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT02952573` - Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement	Phase 2
	Completed	`NCT03439280` - A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)	Phase 1/Phase 2